Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence
Archives of Orthopaedic and Trauma Surgery · 12.06.2026 · 146 (1)
DOI: 10.1007/s00402-026-06374-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Orthopaedic and Trauma Surgery, online erschienen am 12.06.2026. Verfasst von Akif Mirioglu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics and Traumatology, Cukurova University, Adana, Turkey. akifmirioglu@hotmail.com. Hauptthemen laut MEDLINE: High-Temperature Requirement A Serine Peptidase 1, Giant Cell Tumor of Bone, Neoplasm Recurrence, Local, Bone Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cukurova University.
Abstract (Originalsprache)
Introduction
Giant cell tumor of bone (GCTB) is a locally aggressive tumor with a considerable risk of recurrence, but reliable predictive markers are limited. High-temperature requirement A serine peptidase 1 (HtrA1) has been implicated in the progression of several cancers and may also play a role in GCTB recurrence. Materials and methods This retrospective study included 34 patients with GCTB treated with curettage between 2002 and 2016. HtrA1 expression was evaluated separately in giant cells (GC) and mononuclear cells (MNC) using immunohistochemistry. Based on high or low expression in each cell type, patients were categorized into four expression patterns: High GC / High MNC, High GC / Low MNC, Low GC / High MNC, and Low GC / Low MNC. Clinical data, including recurrence status and time to recurrence, were analyzed.
Results
The High GC / Low MNC group showed the highest recurrence rate at 71.4%, compared with 28.6% in the High GC / High MNC group and 31.6% in the Low GC / Low MNC group. No recurrence was observed in the Low GC / High MNC group, which included only one patient. The High GC / Low MNC group showed a non-significant trend toward higher recurrence compared with all other groups combined, with a similar trend toward shorter recurrence-free survival.
Conclusion
HtrA1 expression patterns in GCTB may provide preliminary insight into recurrence risk. Although no statistically significant association was demonstrated, the observed trends suggest potential prognostic relevance and warrant validation in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics and Traumatology, Cukurova University, Adana, Turkey. akifmirioglu@hotmail.com.
- Department of Orthopaedics and Traumatology, Cukurova University, Adana, Turkey. kali.dalkir@hotmail.com.
- Department of Orthopaedics and Traumatology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.
- Department of Orthopaedics and Traumatology, Cukurova University, Adana, Turkey.
- Department of Pathology, Cukurova University, Adana, Turkey.
- Department of Orthopaedics and Traumatology, Koç University, Istanbul, Turkey.
Förderung
- Cukurova University
Zitieren
APA
Mirioglu, A., Dalkir, K. A., Gokmen, M. Y., Bagir, M., Ates, K. E., Deveci, M. A., Gönlüşen, G., & Ozbarlas, H. S. (2026). Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence. Archives of Orthopaedic and Trauma Surgery, 146(1). https://doi.org/10.1007/s00402-026-06374-5
Vancouver
Mirioglu A, Dalkir KA, Gokmen MY, Bagir M, Ates KE, Deveci MA, et al. Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence. Archives of Orthopaedic and Trauma Surgery. 2026;146(1). doi:10.1007/s00402-026-06374-5
BibTeX
@article{Mirioglu2026,
author = {Mirioglu, Akif and Dalkir, Kaan Ali and Gokmen, Mehmet Yigit and Bagir, Melih and Ates, Kivilcim Eren and Deveci, Mehmet Ali and Gönlüşen, Gülfiliz and Ozbarlas, Hilmi Serdar},
title = {Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence},
journal = {Archives of Orthopaedic and Trauma Surgery},
year = {2026},
volume = {146},
number = {1},
doi = {10.1007/s00402-026-06374-5}
}
EUVIMED